Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. SPY
2. AVAV
3. NVDA
4. EOSE
5. NKE
6. MU
7. DLR
8. AAPL
9. TSLA
10. VSH

Go back to Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 5c

August 1, 2019 7:33 AM EDT

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.47), $0.05 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $462 thousand versus the consensus estimate of $430 thousand.

This is an exciting time for Syros as we continue to advance our clinical-stage programs toward multiple data readouts this year and next that... More